Q3 2017 EPS Estimates for Gilead Sciences, Inc. Boosted by Leerink Swann (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Leerink Swann raised their Q3 2017 earnings per share estimates for Gilead Sciences in a report released on Thursday. Leerink Swann analyst G. Porges now forecasts that the biopharmaceutical company will post earnings per share of $2.32 for the quarter, up from their prior estimate of $2.26. Leerink Swann has a “Market Perform” rating and a $89.00 price target on the stock.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the firm posted $3.08 EPS. The firm’s quarterly revenue was down 8.2% on a year-over-year basis.
COPYRIGHT VIOLATION WARNING: “Q3 2017 EPS Estimates for Gilead Sciences, Inc. Boosted by Leerink Swann (GILD)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/10/q3-2017-eps-estimates-for-gilead-sciences-inc-boosted-by-leerink-swann-gild.html.
Other equities research analysts have also issued research reports about the stock. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Jefferies Group LLC restated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 4th. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a research note on Monday, July 17th. Deutsche Bank AG started coverage on shares of Gilead Sciences in a research note on Friday, June 23rd. They issued a “buy” rating and a $79.00 price target on the stock. Finally, Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price target on the stock. in a research note on Wednesday, June 21st. Twelve analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $85.66.
Gilead Sciences (NASDAQ:GILD) opened at 81.98 on Monday. The firm has a market cap of $107.06 billion, a PE ratio of 8.90 and a beta of 1.14. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27. The firm’s 50-day moving average price is $81.25 and its 200 day moving average price is $71.82.
Several large investors have recently modified their holdings of GILD. Waldron LP boosted its stake in shares of Gilead Sciences by 20.4% during the 1st quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 1,752 shares during the period. Hikari Power Ltd boosted its stake in shares of Gilead Sciences by 32.6% during the 1st quarter. Hikari Power Ltd now owns 51,700 shares of the biopharmaceutical company’s stock valued at $3,511,000 after buying an additional 12,700 shares during the period. Physicians Financial Services Inc. lifted its stake in shares of Gilead Sciences by 34.2% in the 1st quarter. Physicians Financial Services Inc. now owns 15,590 shares of the biopharmaceutical company’s stock valued at $1,059,000 after purchasing an additional 3,975 shares during the last quarter. Narwhal Capital Management lifted its stake in shares of Gilead Sciences by 17.0% in the 1st quarter. Narwhal Capital Management now owns 30,655 shares of the biopharmaceutical company’s stock valued at $2,082,000 after purchasing an additional 4,465 shares during the last quarter. Finally, Stonebridge Capital Management Inc. lifted its stake in shares of Gilead Sciences by 11.7% in the 1st quarter. Stonebridge Capital Management Inc. now owns 61,680 shares of the biopharmaceutical company’s stock valued at $4,189,000 after purchasing an additional 6,450 shares during the last quarter. 73.98% of the stock is owned by institutional investors.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock valued at $39,298,919 in the last three months. Company insiders own 1.30% of the company’s stock.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.